BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 11169016)

  • 1. Homocysteine and transmethylations in uremia.
    Perna AF; Ingrosso D; Castaldo P; Galletti P; De Santo NG
    Kidney Int Suppl; 2001 Feb; 78():S230-3. PubMed ID: 11169016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Possible mechanisms of homocysteine toxicity.
    Perna AF; Ingrosso D; Lombardi C; Acanfora F; Satta E; Cesare CM; Violetti E; Romano MM; De Santo NG
    Kidney Int Suppl; 2003 May; (84):S137-40. PubMed ID: 12694330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic consequences of hyperhomocysteinemia in uremia.
    Perna AF; Ingrosso D; Satta E; Romano M; Cimmino A; Galletti P; Zappia V; De Santo NG
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 1):S85-90. PubMed ID: 11576929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse effects of hyperhomocysteinemia and their management by folic acid.
    Perna AF; De Santo NG; Ingrosso D
    Miner Electrolyte Metab; 1997; 23(3-6):174-8. PubMed ID: 9387111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperhomocysteinemia and cardiovascular disease in uremia: the newest evidence in epidemiology and mechanisms of action.
    Perna AF; Acanfora F; Satta E; Lombardi C; Ingrosso D; De Santo NG
    Semin Nephrol; 2004 Sep; 24(5):426-30. PubMed ID: 15490404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homocysteine, a new crucial element in the pathogenesis of uremic cardiovascular complications.
    Perna AF; Ingrosso D; Castaldo P; De Santo NG; Galletti P; Zappia V
    Miner Electrolyte Metab; 1999; 25(1-2):95-9. PubMed ID: 10207268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperhomocysteinemia and macromolecule modifications in uremic patients.
    Perna AF; Capasso R; Lombardi C; Acanfora F; Satta E; Ingrosso D
    Clin Chem Lab Med; 2005; 43(10):1032-8. PubMed ID: 16197294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homocysteine in uremia.
    Perna AF; Ingrosso D; Lombardi C; Cesare CM; Acantora F; Satta E; De Santo NG
    Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S123-6. PubMed ID: 12612968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic consequences of folate-induced reduction of hyperhomocysteinemia in uremia.
    Perna AF; Ingrosso D; De Santo NG; Galletti P; Brunone M; Zappia V
    J Am Soc Nephrol; 1997 Dec; 8(12):1899-905. PubMed ID: 9402092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hyperhomocysteinemia in chronic renal failure.].
    Satta E; Perna AF; Lombardi C; Acanfora F; Violetti E; Romano MM; Capasso R; Pisano M; Paduano F; De Santo NG
    G Ital Nefrol; 2006; 23(5):480-9. PubMed ID: 17123261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Homocysteine and chronic renal failure.
    Perna AF; Castaldo P; De Santo NG; Galletti P; Ingrosso D
    Miner Electrolyte Metab; 1999; 25(4-6):279-85. PubMed ID: 10681652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperhomocysteinemia in uremia--a red flag in a disrupted circuit.
    Perna AF; Ingrosso D; Violetti E; Luciano MG; Sepe I; Lanza D; Capasso R; Ascione E; Raiola I; Lombardi C; Stenvinkel P; Massy Z; De Santo NG
    Semin Dial; 2009; 22(4):351-6. PubMed ID: 19708980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxic effects of hyperhomocysteinemia in chronic renal failure and in uremia: cardiovascular and metabolic consequences.
    Perna AF; Capasso R; Acanfora F; Satta E; Lombardi C; Ingrosso D; Violetti E; Romano MM; De Santo NG
    Semin Nephrol; 2006 Jan; 26(1):20-3. PubMed ID: 16412820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is homocysteine toxic in uremia?
    Perna AF; Luciano MG; Pulzella P; Satta E; Capasso R; Lombardi C; Ingrosso D; De Santo NG
    J Ren Nutr; 2008 Jan; 18(1):12-7. PubMed ID: 18089438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homocysteine, a new cardiovascular risk factor, is also a powerful uremic toxin.
    Perna AF; Castaldo P; Ingrosso D; De Santo NG
    J Nephrol; 1999; 12(4):230-40. PubMed ID: 10493566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma proteins containing damaged L-isoaspartyl residues are increased in uremia: implications for mechanism.
    Perna AF; Castaldo P; De Santo NG; di Carlo E; Cimmino A; Galletti P; Zappia V; Ingrosso D
    Kidney Int; 2001 Jun; 59(6):2299-308. PubMed ID: 11380834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roles of homocysteine in cell metabolism: old and new functions.
    Medina M; Urdiales JL; Amores-Sánchez MI
    Eur J Biochem; 2001 Jul; 268(14):3871-82. PubMed ID: 11453979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternate reasons for atherogenesis in uremia.
    Cohen BD; Patel H; Kornhauser RS
    Proc Clin Dial Transplant Forum; 1977; 7():178-80. PubMed ID: 150596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The methionine-homocysteine cycle and its effects on cognitive diseases.
    Miller AL
    Altern Med Rev; 2003 Feb; 8(1):7-19. PubMed ID: 12611557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperhomocysteinemia: an additional cardiovascular risk factor.
    Fanapour PC; Yug B; Kochar MS
    WMJ; 1999 Dec; 98(8):51-4. PubMed ID: 10639897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.